Spine surgery company Carlsmed Inc reported on Friday the availability of the aprevo patient-specific spine technology as well as the launch of New Technology Add-On Payment (NTAP) reimbursement across the US spine market.

Effective immediately, the spine fusion procedures utilizing the company aprevo devices are eligible for additional reimbursement from CMS and private payors through the NTAP programme.

The company said its aprevo devices are designed to improve the standard of care for the surgical treatment of patients with adult spinal malalignment. It uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo spine fusion devices to align with the surgeon's goals for each patient.

According to the company, the aprevo devices are US FDA cleared and have been granted US FDA Breakthrough Designation, an industry first for any implanted device and are commercially available in the US.